ME00122B - Sistemi koji obezbjeđuju podržano oslobađanje lijeka - Google Patents
Sistemi koji obezbjeđuju podržano oslobađanje lijekaInfo
- Publication number
- ME00122B ME00122B MEP-2008-200A MEP2008200A ME00122B ME 00122 B ME00122 B ME 00122B ME P2008200 A MEP2008200 A ME P2008200A ME 00122 B ME00122 B ME 00122B
- Authority
- ME
- Montenegro
- Prior art keywords
- coating layer
- inner core
- agent
- effective agent
- impermeable
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract 11
- 238000013268 sustained release Methods 0.000 title claims abstract 7
- 239000012730 sustained-release form Substances 0.000 title claims abstract 7
- 239000011247 coating layer Substances 0.000 claims abstract 57
- 239000003795 chemical substances by application Substances 0.000 claims abstract 31
- 238000000034 method Methods 0.000 claims abstract 18
- 230000009885 systemic effect Effects 0.000 claims abstract 5
- 230000000144 pharmacologic effect Effects 0.000 claims abstract 4
- 230000001766 physiological effect Effects 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000013269 sustained drug release Methods 0.000 claims 8
- 239000010410 layer Substances 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960002963 ganciclovir Drugs 0.000 claims 2
- 229960000715 nimodipine Drugs 0.000 claims 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 2
- 229920001296 polysiloxane Polymers 0.000 claims 2
- 238000004073 vulcanization Methods 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
Obezbeđeni su postupak i sistem za tretiranje organizma sisara radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta. Postupak obuhvata primenu sistema za isporuku leka sa podržanim oslobađanjem leka u organizmu sisara koji treba takav tretman na područje gde se želi oslobađanje efektivnog agensa gde postupak obezbeđuje da efektivni agens prolazi kroz sistem na kontrolisan način. Sistem obuhvata unutrašnje jezgro ili rezervoar koji obuhvata efektivni agens; prvi prevlačeći sloj koji je propustljiv za prolazak efektivnog agensa; drugi prevlačeći sloj koji je uglavnom nepropustljiv za prolazak efektivnog agensa; i treći prevlačeći sloj, koji je propustljiv za prolazak efektivnog agensa. Prvi prevlačeći sloj prekriva bar deo unutrašnjeg jezgra. Drugi prevlačeći sloj prekriva bar deo prvog prevlačećeg sloja i unutrašnjeg jezgra; gde bar mali deo prvog prevlačećeg sloja ili unutrašnjeg jezgra nije prekriven sa drugim prevlačećem slojem. Drugi prevlačeći sloj obuhvata nepropustljiv film i bar jedan nepropustljiv disk. Treći prevlačeći sloj uglavnom potpuno prekriva drugi prevlačeći sloj i neprevlačeni deo prvog prevlačećeg sloja •ili unutrašnjeg jezgra. Obezbeđeni su postupak i sistem za tretiranje organizma sisara radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta. Postupak obuhvata primenu sistema za isporuku leka sa podržanim oslobađanjem leka u organizmu sisara koji treba takav tretman na područje gde se želi oslobađanje efektivnog agensa gde postupak obezbeđuje da efektivni agens prolazi kroz sistem na kontrolisan način. Sistem obuhvata unutrašnje jezgro ili rezervoar koji obuhvata efektivni agens; prvi prevlačeći sloj koji je propustljiv za prolazak efektivnog agensa; drugi prevlačeći sloj koji je uglavnom nepropustljiv za prolazak efektivnog agensa; i treći prevlačeći sloj, koji je propustljiv za prolazak efektivnog agensa. Prvi prevlačeći sloj prekriva bar deo unutrašnjeg jezgra. Drugi prevlačeći sloj prekriva bar deo prvog prevlačećeg sloja i unutrašnjeg jezgra; gde bar mali deo prvog prevlačećeg sloja ili unutrašnjeg jezgra nije prekriven sa drugim prevlačećem slojem. Drugi prevlačeći sloj obuhvata nepropustljiv film i bar jedan nepropustljiv disk. Treći prevlačeći sloj uglavnom potpuno prekriva drugi prevlačeći sloj i neprevlačeni deo prvog prevlačećeg sloja •ili unutrašnjeg jezgra.
Claims (21)
1. Postupak za obezbeđivanje kontrolisane i podržane primene agensa koji je efektivan u dobijanju željenog lokalnog ili sistemskog fiziološkog ili fannakološkog efekta, naznačen time, što obuhvata: hiruršku implataciju sistema za isporuku leka sa podržanim oslobađanjem na željenu lokaciju, pomenuti sistem za isporuku Jeka obuhvata:(l) unutrašnje jezgro ili rezervoar koji obuhvata efektivnu količinu agensakoja je efektivna za dobijanje željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta,(2) prvi prevlčeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti prvi prevlačeći sloj prekriva bar deo pomenutog unutrašnjeg jezgra, koji obezbeđuje kontrolu ipodržano oslobađanje agensa,(3) drugi prevlačeći sloj, pomenuti drugi prevlačeći sloj je uglavnom nepropustljiv na prolazak pomenutog agensa, i pomenuti drugi prevlačeći sloj koji prekriva bar 50% unutrašnjeg jezgra i/ili prvog prevlačećeg sloja, gde bar mali deo unutrašnjeg jezgra ili prvog prevlačećeg sloja nije prekriven sa pomenutim drugim prevlačećim slojem i pomenuti drugi prevlačeći sloj obuhvata nepropustljivi film i bar jedan nepropustljivi disk koji je od različitog matreijala ili koji ima uglavnom veću tvrdoću, debljinu, rastegljivost ili odgovor na toplotno vulkanizovanje nego što je nepropustljivi film, i(4) treći prevlačeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti treći prevlačeći sloj uglavnom potpuno prekriva pomenuti drugi prevlačeći sloj i nepokriveni deo prvog prevlačećeg sloja ili unutrašnjeg jezgra, tako da pomenuti agens može da prođe korz pomenuti treći prevlačeći sloj na kontrolisani način.
2.postupak prema zahtevu 1, naznačen time, što pomenuti prvi i trći prevlačeći slojevi obuhvataju polivinil alkohol.
3.Postupak prema zahtevu l, naznačen time, što pomenuti treći prevlačeći sloj je silikon.
4.Postupak prema zahtevu 2, naznačen time, što pomenuti drugi prevlačeći sloj obuhvata etilen vinil acetat.
5.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je ganciklovir ili 5-fluororacuil.
6.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je nisko rastvoran steroid.
7.Postupak prema zahtevu 6, naznačen time, što pomenuti nisko rastvoran steroid je fluocinolon acetonid.
8.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je neuroprotektant. .. 15
9.Postupak prema zahtevu 8, naznačen time, što pomenuti neuroprotektant je nimodipin. l O.
10. Sistem za isporuku leka sa podržanim oslobađanjem leka, naznačen time, što obuhvata: (A) unutrašnje jezgro ili rezervoar koji obuhvata efektivnu količinu agensa radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta, (B) prvi prevlčeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti prvi prevlačeći sloj prekriva bar deo pomenutog unutrašnjeg jezgra, koji obezbeđuje kontrolu i podržano oslobađanje agensa, (C) drugi prevlačeći sloj, pomenuti drugi prevlačeći sloj je uglavnom nepropustljiv na prolazak pomenutog agensa, i pomenuti drugi prevlačeći sloj koji prekriva bar 50% unutrašnjeg jezgra i/ili prvog prevlačećeg sloja, gde bar mali deo unutrašnjeg jezgra ili prvog prevlačećeg sloja nije prekriven sa pomenutim drugim prevlačećim slojem i pomenuti drugi prevlačeći sloj obuhvata nepropustljivi film i bar jedan nepropustljivi disk koji je od različitog matreijala ili koji ima uglavnom veću tvrdoću, debljinu, rastegljivost ili odgovor na toplotno vulkanizovanje nego što ima nepropustljiv film, i (D) treći prevlačeći sloj, pomenuti prevlačeći sloj je propustljiv za prolazak pomenutog efektivnog agensa, gde pomenuti treći prevlačeći sloj uglavnom potpuno prekriva pomenuti drugi prevlačeći sloj i nepokriveni deo prvog prevlačećeg sloja ili unutrašnjeg jezgra.
11.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu l O, naznačen time, što pomenuti treći prevlačeći sloj obuhvata polivinil alkohol
12.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu ll , naznačen time, što pomenuti drugi prevlačeći sloj obuhvata etilen vinil acetat.
13.Sistem za isporuku teka sa podržanim oslobađanjem leka prema zahtevu 12, naznačen time, što pomenuti prvi prevlačeći sloj obuhvata polivinil akohol.
14. Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 13, naznačen time, što pomenuti efektivni agens je ganciklover ili fluocinolon acetonid.
15.Sistem za isporuku teka sa podržanim oslobađanjem teka prema zahtevu 1O, naznačen time, što pomenuti efektivni agens je nimodipin.
16.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu l O, naznačen time, što treći prevlačeći sloj obuhvata silikon.
17.Postupak prema zahtevu l, naznačen time, što pomenuti nepropustljivi film je načinjen od matreijala koji se razlikuje od onog za pomenuti nepropustljivi disk.
18.Postupak prema zahtevu l, naznačen time, što pomenuti drugi prevlačeći sloj pokriva celokupno unutrašnje jezgro iprvi prevlačeći sloj sa izuzetkom difuzionog otvora. .. 16
19.Postupak prema zahtevu l, naznačen time, što pomenuti nepropustljivi disk je tvrdi od pomenutog nepropustljivog fllma.
20.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 10, naznačen time, što pomenuti efektivni agens je steroid.
21.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 10, naznačen time, što pomenuti efektivni agens je neuroprotektant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/919,221 US5902598A (en) | 1997-08-28 | 1997-08-28 | Sustained release drug delivery devices |
| PCT/US1998/017342 WO1999011244A1 (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00122B true ME00122B (me) | 2010-10-10 |
Family
ID=25441727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-200/08A MEP20008A (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
| MEP-2008-200A ME00122B (me) | 1997-08-28 | 1998-08-28 | Sistemi koji obezbjeđuju podržano oslobađanje lijeka |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-200/08A MEP20008A (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5902598A (me) |
| EP (1) | EP1009388B1 (me) |
| JP (2) | JP4530531B2 (me) |
| KR (1) | KR20010023358A (me) |
| CN (2) | CN101327197A (me) |
| AR (1) | AR017026A1 (me) |
| AT (1) | ATE548029T1 (me) |
| AU (1) | AU741846B2 (me) |
| BR (1) | BR9811381A (me) |
| CA (1) | CA2301685C (me) |
| CZ (1) | CZ302339B6 (me) |
| EA (1) | EA002162B1 (me) |
| HK (1) | HK1035135A1 (me) |
| HU (1) | HUP0002797A3 (me) |
| IL (1) | IL134568A (me) |
| ME (2) | MEP20008A (me) |
| NO (1) | NO327752B1 (me) |
| NZ (2) | NZ502836A (me) |
| PL (1) | PL344039A1 (me) |
| RS (1) | RS52096B (me) |
| SG (1) | SG121718A1 (me) |
| TR (1) | TR200001029T2 (me) |
| TW (1) | TWI222884B (me) |
| UA (1) | UA71898C2 (me) |
| WO (1) | WO1999011244A1 (me) |
Families Citing this family (271)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6117643A (en) * | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
| WO2000040089A1 (en) * | 1999-01-05 | 2000-07-13 | Massachusetts Eye And Ear Infirmary | Targeted transscleral controlled release drug delivery to the retina and choroid |
| US20040121014A1 (en) * | 1999-03-22 | 2004-06-24 | Control Delivery Systems, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
| ES2315598T3 (es) | 1999-10-21 | 2009-04-01 | Alcon, Inc. | Dispositivo para la administracion de farmacos. |
| JP2003511204A (ja) | 1999-10-21 | 2003-03-25 | アルコン，インコーポレイティド | テノン下薬剤送出 |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US20040208910A1 (en) * | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| US20040175410A1 (en) * | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| US20050074747A1 (en) * | 2000-09-08 | 2005-04-07 | Wadih Arap | Biopanning and rapid analysis of selective interactive ligands (brasil) |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US20040170955A1 (en) * | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| IL155479A0 (en) | 2000-11-03 | 2003-11-23 | Control Delivery Sys Inc | Improved device and method for treating conditions of a joint |
| DE60114229T2 (de) | 2000-11-29 | 2006-07-06 | Allergan, Inc., Irvine | Verhinderung von transplantatabstossung im auge |
| US6756049B2 (en) | 2000-12-29 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
| EP1847255A3 (en) * | 2001-01-03 | 2009-03-04 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with coated drug cores |
| EP1404295B1 (en) * | 2001-01-03 | 2007-10-10 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with coated drug cores |
| WO2002053128A2 (en) | 2001-01-03 | 2002-07-11 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
| CA2432225C (en) * | 2001-01-03 | 2008-01-15 | Michael J. Brubaker | Sustained release drug delivery devices with prefabricated permeable plugs |
| US6991808B2 (en) * | 2001-01-26 | 2006-01-31 | Bausch & Lomb Inc. | Process for the production of sustained release drug delivery devices |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US8541021B2 (en) * | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| AU2002316053A1 (en) * | 2001-05-01 | 2002-11-11 | A.V. Topchiev Institute Of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
| DE60233217D1 (de) | 2001-05-01 | 2009-09-17 | Corium Internat Inc | Hydrogel-zusammensetzungen |
| US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| US7883717B2 (en) * | 2001-06-12 | 2011-02-08 | Johns Hopkins University | Reservoir device for intraocular drug delivery |
| WO2003007979A1 (en) * | 2001-07-18 | 2003-01-30 | Board Of Regents, The University Of Texas System | An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| ES2271301T3 (es) * | 2001-07-23 | 2007-04-16 | Alcon, Inc. | Dispositivo de suministro de farmaco oftalmico. |
| PT1409065E (pt) | 2001-07-23 | 2007-03-30 | Alcon Inc | Dispositivo de administração de fármacos oftálmicos |
| US7749528B2 (en) * | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| CA2456025C (en) | 2001-08-29 | 2011-11-22 | Ricardo A.P. De Carvalho | An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US20040048243A1 (en) * | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
| US20030158598A1 (en) * | 2001-09-17 | 2003-08-21 | Control Delivery Systems, Inc. | System for sustained-release delivery of anti-inflammatory agents from a coated medical device |
| EP1469723B1 (en) * | 2002-01-31 | 2006-11-22 | Disease Control Textiles SA | Laminated insecticide dispenser |
| US20030229333A1 (en) * | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
| US7621907B2 (en) * | 2002-03-11 | 2009-11-24 | Alcon, Inc. | Implantable drug delivery system |
| JP5578388B2 (ja) | 2002-04-18 | 2014-08-27 | オプコ ファーマシューティカルズ、エルエルシー | 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法 |
| WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| AU2003234294A1 (en) * | 2002-05-02 | 2003-11-17 | Control Delivery Systems, Inc. | Device and method for treating conditions of a joint |
| US8871241B2 (en) * | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| AU2003234439A1 (en) * | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| US7442711B2 (en) | 2002-05-17 | 2008-10-28 | Othera Holding, Inc. | Amelioration of the development of cataracts and other ophthalmic diseases |
| MXPA05000632A (es) * | 2002-07-15 | 2005-03-31 | Alcon Inc | Composiciones para implante farmaceuticas, lipofilas, no polimericas para uso intraocular. |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| AU2003301347A1 (en) * | 2002-10-17 | 2004-05-04 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| AU2003287666A1 (en) * | 2002-11-13 | 2004-06-03 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| CA2729967C (en) * | 2002-12-13 | 2018-01-16 | Schering-Plough Healthcare Products, Inc. | Use of a transdermal or transmucosal ingredient delivery device |
| WO2004058272A1 (en) * | 2002-12-20 | 2004-07-15 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| ATE477337T1 (de) | 2003-01-16 | 2010-08-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur sirna-hemmung von icam-1 |
| DK1592407T3 (da) * | 2003-01-24 | 2010-04-19 | Psivida Inc | Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af carbonanhydraseinhibitorer |
| SI1592408T1 (sl) * | 2003-01-24 | 2010-01-29 | Psivida Inc | Naprava s podaljšanim sproščanjem in postopek za okularno dajanje adrenergičnih sredstev |
| MXPA05007717A (es) * | 2003-01-24 | 2005-09-30 | Control Delivery Sys Inc | Liberacion controlada de agentes altamente solubles. |
| US20050019400A1 (en) * | 2003-01-27 | 2005-01-27 | Deveney Thomas William | Controlled-release drug delivery system |
| WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| US9445901B2 (en) * | 2003-03-12 | 2016-09-20 | Deger C. Tunc | Prosthesis with sustained release analgesic |
| US7037521B2 (en) * | 2003-03-28 | 2006-05-02 | Bausch & Lomb Incorporated | Using a laser for cutting a hole in a capsule for controlled drug delivery |
| US20050261668A1 (en) * | 2003-03-28 | 2005-11-24 | Bausch & Lomb Incorporated | Drug delivery device |
| US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
| US7825134B2 (en) * | 2003-05-19 | 2010-11-02 | Othera Holding, Inc. | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| US8029477B2 (en) * | 2003-12-19 | 2011-10-04 | Ethicon Endo-Surgery, Inc. | Applier with safety for implantable medical device |
| US7862546B2 (en) * | 2003-06-16 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Subcutaneous self attaching injection port with integral moveable retention members |
| US7561916B2 (en) | 2005-06-24 | 2009-07-14 | Ethicon Endo-Surgery, Inc. | Implantable medical device with indicator |
| US8715243B2 (en) * | 2003-06-16 | 2014-05-06 | Ethicon Endo-Surgery, Inc. | Injection port applier with downward force actuation |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
| US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
| US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| WO2006071794A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
| CA2530416C (en) * | 2003-06-27 | 2015-08-25 | Ethicon, Incorporated | Postpartum cells derived from placental tissue, and methods of making and using the same |
| US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US20050054586A1 (en) * | 2003-06-30 | 2005-03-10 | Bartels Stephen P. | Treatment of ophthalmic disorders |
| US20040265356A1 (en) * | 2003-06-30 | 2004-12-30 | Bausch & Lomb Incorporated | Drug delivery device |
| EP1648363B1 (en) * | 2003-07-03 | 2019-03-06 | Corium International, Inc. | Wound dressing, ingredient delivery device and iv hold-down, and method relating to same |
| MXPA05011517A (es) * | 2003-07-10 | 2005-12-12 | Alcon Inc | Dispositivo para el suministro de medicamentos oftalmicos. |
| CA2539324A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| MXPA06005431A (es) * | 2003-11-13 | 2007-01-25 | Psivida Inc | Dispositivos de suministro de liberacion sostenida inyectables. |
| AU2004293105B2 (en) | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US8162897B2 (en) * | 2003-12-19 | 2012-04-24 | Ethicon Endo-Surgery, Inc. | Audible and tactile feedback |
| US20050148948A1 (en) * | 2003-12-19 | 2005-07-07 | Caputa Steven G. | Sutureless ophthalmic drug delivery system and method |
| DE10360185A1 (de) * | 2003-12-20 | 2005-08-04 | Max Wyssmann | Vorrichtung zur gezielten, steuerbaren Abgabe oder zum Ansaugen einer Flüssigkeit oder einer viskosen Masse |
| US7211272B2 (en) * | 2003-12-22 | 2007-05-01 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050158365A1 (en) * | 2003-12-22 | 2005-07-21 | David Watson | Drug delivery device with mechanical locking mechanism |
| US20050136095A1 (en) * | 2003-12-22 | 2005-06-23 | Brian Levy | Drug delivery device with suture ring |
| US20050137538A1 (en) | 2003-12-22 | 2005-06-23 | Bausch & Lomb Incorporated | Drug delivery device |
| US20070053963A1 (en) * | 2004-01-13 | 2007-03-08 | Hotchkiss Robert N | Drug delivery to a joint |
| CA2554424A1 (en) * | 2004-01-26 | 2005-08-11 | Control Delivery Systems, Inc. | Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| KR20070007299A (ko) | 2004-01-30 | 2007-01-15 | 코리움 인터네셔널, 인크. | 활성제의 전달을 위한 급속 용해 필름 |
| US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| NZ551379A (en) * | 2004-05-25 | 2010-11-26 | Othera Holding Inc | Oculoselective drugs and prodrugs |
| WO2006004795A2 (en) | 2004-06-25 | 2006-01-12 | The Johns Hopkins University | Angiogenesis inhibitors |
| US7922702B2 (en) | 2004-07-02 | 2011-04-12 | Qlt Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
| US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| WO2006017807A2 (en) * | 2004-08-05 | 2006-02-16 | Corium International, Inc. | Adhesive composition |
| US20060067978A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly(vinyl alcohol) drug delivery devices |
| US20060068012A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
| US20060067979A1 (en) * | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Ophthalmic drug release device for multiple drug release |
| US20060067980A1 (en) * | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Capsule for encasing tablets for surgical insertion into the human body |
| US20060078592A1 (en) * | 2004-10-12 | 2006-04-13 | Bausch & Lomb Incorporated | Drug delivery systems |
| US20070276481A1 (en) * | 2004-12-08 | 2007-11-29 | Renner Steven B | Drug delivery device |
| US20060134162A1 (en) * | 2004-12-16 | 2006-06-22 | Larson Christopher W | Methods for fabricating a drug delivery device |
| US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
| WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
| WO2006083394A2 (en) * | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
| US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| WO2006068898A1 (en) * | 2004-12-22 | 2006-06-29 | Bausch & Lomb Incorporated | Reusable drug delivery device |
| US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| CA2589063C (en) | 2004-12-23 | 2016-08-09 | Ethicon Incorporated | Treatment of parkinson's disease and related disorders using postpartum derived cells |
| CN104147005B (zh) | 2005-02-09 | 2018-07-03 | 参天制药株式会社 | 用于治疗疾病或病症的液体制剂 |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2006102378A2 (en) * | 2005-03-21 | 2006-09-28 | Macusight, Inc. | Drug delivery systems for treatment of diseases or conditions |
| JP2008535847A (ja) * | 2005-04-08 | 2008-09-04 | サーモディクス，インコーポレイティド | 網膜下に送達するための持続放出インプラント |
| WO2006127592A2 (en) * | 2005-05-26 | 2006-11-30 | Othera Pharmaceuticals, Inc. | Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts |
| US7651483B2 (en) * | 2005-06-24 | 2010-01-26 | Ethicon Endo-Surgery, Inc. | Injection port |
| US7918844B2 (en) | 2005-06-24 | 2011-04-05 | Ethicon Endo-Surgery, Inc. | Applier for implantable medical device |
| US20060292202A1 (en) * | 2005-06-27 | 2006-12-28 | Bausch & Lomb Incorporated | Drug delivery device |
| US20100004156A1 (en) | 2005-07-27 | 2010-01-07 | Shalesh Kaushal | Small Compounds That Correct Protein Misfolding and Uses Thereof |
| US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
| US20080293691A1 (en) | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| JP5289970B2 (ja) * | 2005-12-16 | 2013-09-11 | エシコン・インコーポレイテッド | 組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法 |
| ES2628129T3 (es) * | 2005-12-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto |
| US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| AU2007212271B2 (en) | 2006-02-09 | 2012-11-01 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
| US20070203190A1 (en) * | 2006-02-22 | 2007-08-30 | Ghanshyam Patil | Hydroxylamines and derivatives for the inhibition of complement activation |
| DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
| JP5208916B2 (ja) | 2006-03-31 | 2013-06-12 | キュー エル ティー インク． | 鼻涙系用の薬物送達方法、構造および組成物 |
| WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| PT2029746E (pt) * | 2006-06-12 | 2012-10-15 | Exegenics Inc D B A Opko Health Inc | Composições e métodos para a inibição do sirna de angiogenese |
| US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| ATE549022T1 (de) | 2006-08-07 | 2012-03-15 | Bausch & Lomb | Behandlung von infektionen und deren folgeleiden mit kombinierten dissoziierten glocucorticoid- rezeptor-agonisten und antiinfektionswirkstoffen |
| DK2056799T3 (da) * | 2006-08-31 | 2013-10-28 | Bausch & Lomb | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af glaukom eller progression deraf |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| US20110105559A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy |
| DK2061444T3 (da) * | 2006-09-11 | 2011-06-27 | Bausch & Lomb | Sammensætninger og fremgangsmåder til behandling, kontrol, reducering, forbedring eller forebyggelse af allergi |
| US20110104159A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| US20080145405A1 (en) * | 2006-12-15 | 2008-06-19 | Kunzler Jay F | Drug delivery devices |
| GB0713463D0 (en) | 2007-07-11 | 2007-08-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| US20080280890A1 (en) | 2007-02-22 | 2008-11-13 | Ghanshyam Patil | Hydroxylamine compounds and methods of their use |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| US20090042936A1 (en) * | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
| US20090087443A1 (en) * | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
| BRPI0818183A2 (pt) * | 2007-10-05 | 2019-07-16 | Ethicon Inc | reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano |
| US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
| EP2471572A3 (en) * | 2008-04-17 | 2012-10-17 | Allergan, Inc. | Implantable access port device |
| US9023063B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device having a safety cap |
| US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| US20100121441A1 (en) * | 2008-11-10 | 2010-05-13 | Nabil Jabbour | Surgical implant and method |
| US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
| WO2010077732A2 (en) * | 2008-12-09 | 2010-07-08 | Aether Medical Llc | Implantable analgesic |
| EP2379087B1 (en) * | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
| CA2747758C (en) * | 2008-12-19 | 2020-09-22 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
| US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| PL2379088T3 (pl) | 2008-12-19 | 2018-07-31 | DePuy Synthes Products, Inc. | Leczenie płuca oraz chorób i zaburzeń płucnych |
| EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
| AU2010208046B2 (en) | 2009-01-29 | 2014-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| EP2411504B1 (en) * | 2009-03-26 | 2017-05-10 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells as therapy for alzheimer's disease |
| US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
| US8632511B2 (en) * | 2009-05-06 | 2014-01-21 | Alcon Research, Ltd. | Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device |
| CN102655823B (zh) * | 2009-05-18 | 2016-04-20 | 多斯医学公司 | 药物洗脱眼植入物 |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| ES2921527T3 (es) | 2009-06-03 | 2022-08-29 | Forsight Vision5 Inc | Administración de fármaco en segmento anterior |
| IN2012DN00352A (me) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| US8715158B2 (en) | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
| US8506532B2 (en) | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
| US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
| US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| EP2507373A4 (en) * | 2009-12-04 | 2013-08-07 | Opko Pharmaceuticals Llc | COMPOSITIONS AND METHODS FOR INHIBITING VEGF |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| US20110238036A1 (en) * | 2009-12-23 | 2011-09-29 | Psivida Us, Inc. | Sustained release delivery devices |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| US20110189174A1 (en) * | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| US8882728B2 (en) | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
| US20110270021A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Electronically enhanced access port for a fluid filled implant |
| US20110270025A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Remotely powered remotely adjustable gastric band system |
| US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
| JP2013526572A (ja) * | 2010-05-17 | 2013-06-24 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 眼治療薬の送達のための薬物送達装置 |
| EP2585057B1 (en) | 2010-06-25 | 2017-08-23 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methods of treatment using sterculic acid |
| DK2600930T3 (da) | 2010-08-05 | 2021-03-01 | Forsight Vision4 Inc | Injektionsapparat til lægemiddelafgivelse |
| WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| ES2894940T3 (es) | 2010-08-05 | 2022-02-16 | Forsight Vision4 Inc | Aparato para tratar un ojo |
| US20120041258A1 (en) | 2010-08-16 | 2012-02-16 | Allergan, Inc. | Implantable access port system |
| US20120065460A1 (en) | 2010-09-14 | 2012-03-15 | Greg Nitka | Implantable access port system |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| EP2651399A2 (en) | 2010-12-13 | 2013-10-23 | Purdue Pharma LP | Controlled release dosage forms |
| US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US20120316199A1 (en) | 2011-06-07 | 2012-12-13 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
| AU2012271728B2 (en) | 2011-06-14 | 2016-10-20 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
| US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
| DK2750660T3 (en) | 2011-08-29 | 2016-12-12 | Mati Therapeutics Inc | FILING WITH PROLONGED RELEASE OF ACTIVE AGENTS to treat glaucoma and ocular hypertension |
| US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
| EP2755615B1 (en) | 2011-09-14 | 2022-04-06 | Forsight Vision5, Inc. | Ocular insert apparatus |
| EP3903733A1 (en) | 2011-09-16 | 2021-11-03 | ForSight Vision4, Inc. | Fluid exchange apparatus |
| WO2013058809A1 (en) | 2011-10-19 | 2013-04-25 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
| US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
| US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
| AU2012346214B2 (en) | 2011-11-30 | 2017-09-14 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| AU2012346537A1 (en) | 2011-12-01 | 2014-07-17 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| ES2676556T3 (es) | 2011-12-23 | 2018-07-20 | Depuy Synthes Products Llc | Detección de células derivadas de tejido del cordón umbilical humano |
| US10080648B2 (en) | 2012-01-24 | 2018-09-25 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US10028824B2 (en) | 2012-01-24 | 2018-07-24 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US9364316B1 (en) * | 2012-01-24 | 2016-06-14 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| CA3177993A1 (en) | 2012-01-24 | 2013-08-01 | The Regents Of The University Of Colorado, A Body Corporate | Modular intraocular lens designs and methods |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| KR101969594B1 (ko) * | 2012-05-11 | 2019-04-16 | 서강대학교산학협력단 | 안내 약물 전달 임플란트 |
| AU2013334169B2 (en) | 2012-10-26 | 2018-03-29 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
| CA2940513C (en) | 2013-03-11 | 2023-08-15 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for ocular inflammation |
| WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| ES2972168T3 (es) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Implante oftálmico para administración de sustancias terapéuticas |
| US10098836B2 (en) | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
| AU2014350095B9 (en) * | 2013-11-14 | 2019-09-12 | Eyed Pharma | Eye device |
| JP2016538050A (ja) * | 2013-11-15 | 2016-12-08 | グローコス コーポレーション | 安定な薬物製剤を貯蔵及び放出するように構成された眼内インプラント |
| EP4215159A1 (en) | 2014-02-18 | 2023-07-26 | Alcon Inc. | Modular intraocular lens designs, tools and methods |
| US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US9580896B2 (en) | 2014-07-05 | 2017-02-28 | John David Hopkins | Apparatus and method for prolonged active agent in aqueous systems |
| US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
| BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
| RU2708958C2 (ru) | 2014-11-10 | 2019-12-12 | Форсайт Вижн4, Инк. | Расширяемые устройства доставки лекарственных средств и способы использования |
| EP4523656A2 (en) | 2015-01-30 | 2025-03-19 | Alcon Inc. | Modular intraocular lens designs, tools and methods |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| CA3002085A1 (en) | 2015-11-04 | 2017-05-11 | The Regents Of The University Of Colorado, A Body Corporate | Modular intraocular lens designs, tools and methods |
| WO2017087902A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| WO2017176886A1 (en) | 2016-04-05 | 2017-10-12 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| US11045309B2 (en) | 2016-05-05 | 2021-06-29 | The Regents Of The University Of Colorado | Intraocular lens designs for improved stability |
| JP2019524688A (ja) | 2016-07-05 | 2019-09-05 | ヤンセン バイオテツク，インコーポレーテツド | 前駆細胞を用いた網膜血管疾患の治療 |
| US11382736B2 (en) | 2017-06-27 | 2022-07-12 | Alcon Inc. | Injector, intraocular lens system, and related methods |
| US11103460B2 (en) | 2017-08-07 | 2021-08-31 | Board Of Regents, The University Of Texas System | Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients |
| KR20200093581A (ko) | 2017-11-21 | 2020-08-05 | 포사이트 비젼4, 인크. | 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법 |
| EP3801378A4 (en) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
| SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| US11779739B2 (en) * | 2018-12-21 | 2023-10-10 | Perfect Ip, Llc | Drug delivery system and method |
| JP7451732B2 (ja) | 2020-02-06 | 2024-03-18 | オキュラ セラピューティクス，インコーポレイテッド | 眼疾患を治療するための組成物及び方法 |
| AU2021244485B2 (en) | 2020-03-25 | 2024-05-16 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| EP4216929A1 (en) | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| US11331267B2 (en) | 2020-09-24 | 2022-05-17 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| US11357620B1 (en) | 2021-09-10 | 2022-06-14 | California LASIK & Eye, Inc. | Exchangeable optics and therapeutics |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2961629A (en) * | 1957-02-12 | 1960-11-22 | Lawrence J Kamm | Electrical connector for flexible cable |
| US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3896819A (en) * | 1969-04-01 | 1975-07-29 | Alejandro Zaffaroni | IUD having a replenishing drug reservoir |
| US3618604A (en) * | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3630200A (en) * | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
| US3980463A (en) * | 1970-11-16 | 1976-09-14 | Sumitomo Chemical Company, Limited | Process for producing granular composition for use in agriculture and horticulture |
| US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
| US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
| US4135514A (en) * | 1974-12-23 | 1979-01-23 | Alza Corporation | Osmotic releasing system for administering ophthalmic drug to eye of animal |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
| US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4247498A (en) * | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4519909A (en) * | 1977-07-11 | 1985-05-28 | Akzona Incorporated | Microporous products |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| JPS54119021A (en) * | 1978-03-06 | 1979-09-14 | Nippon Kayaku Co Ltd | Carcinostatic agent |
| US4290426A (en) * | 1978-05-04 | 1981-09-22 | Alza Corporation | Dispenser for dispensing beneficial agent |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| DK90883A (da) * | 1982-03-18 | 1983-09-19 | Merck & Co Inc | Beholder til osmotisk afgivelse af et stof eller en stofblanding |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4475916A (en) * | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4432965A (en) * | 1982-07-09 | 1984-02-21 | Key Pharmaceuticals, Inc. | Quinidine sustained release dosage formulation |
| US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
| US4522625A (en) * | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
| US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
| IT1206166B (it) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione |
| US4692336A (en) * | 1984-03-19 | 1987-09-08 | Alza Corporation | Self controlled release device for administering beneficial agent to recipient |
| US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
| US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
| US4657543A (en) * | 1984-07-23 | 1987-04-14 | Massachusetts Institute Of Technology | Ultrasonically modulated polymeric devices for delivering compositions |
| US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| US4693886A (en) * | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
| US4609374A (en) * | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
| US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
| US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
| US4717567A (en) * | 1985-11-25 | 1988-01-05 | Eastman Kodak Company | Rumen-stable pellets |
| IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US5141752A (en) * | 1986-05-09 | 1992-08-25 | Alza Corporation | Delayed drug delivery device |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4786500A (en) * | 1986-06-26 | 1988-11-22 | Alza Corporation | Programmable agent delivery system |
| JPH0794384B2 (ja) * | 1986-09-01 | 1995-10-11 | 帝国製薬株式会社 | 徐放性口腔内用製剤 |
| US4806382A (en) * | 1987-04-10 | 1989-02-21 | University Of Florida | Ocular implants and methods for their manufacture |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| US4994273A (en) * | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
| IT1223150B (it) * | 1987-11-18 | 1990-09-12 | Ubaldo Conte | Compressa per uso oftalmico e rilascio controllato della sostanza attiva |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| US4882150A (en) * | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US5098443A (en) * | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| US5496557A (en) * | 1990-01-30 | 1996-03-05 | Akzo N.V. | Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances |
| US5091185A (en) * | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
| US5525601A (en) * | 1990-09-07 | 1996-06-11 | Universidad De Alicante | Composition for treating ocular pain |
| IS3778A7 (is) * | 1990-10-31 | 1992-05-02 | Amgen Inc. | Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5435998A (en) * | 1994-08-03 | 1995-07-25 | Abelson; Mark B. | Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents |
-
1997
- 1997-08-28 US US08/919,221 patent/US5902598A/en not_active Expired - Lifetime
-
1998
- 1998-08-27 TW TW087114137A patent/TWI222884B/zh not_active IP Right Cessation
- 1998-08-28 BR BR9811381-0A patent/BR9811381A/pt not_active Application Discontinuation
- 1998-08-28 PL PL98344039A patent/PL344039A1/xx unknown
- 1998-08-28 NZ NZ502836A patent/NZ502836A/xx unknown
- 1998-08-28 CN CNA2007101933400A patent/CN101327197A/zh active Pending
- 1998-08-28 TR TR2000/01029T patent/TR200001029T2/xx unknown
- 1998-08-28 ME MEP-200/08A patent/MEP20008A/xx unknown
- 1998-08-28 KR KR1020007001996A patent/KR20010023358A/ko not_active Application Discontinuation
- 1998-08-28 JP JP2000508347A patent/JP4530531B2/ja not_active Expired - Fee Related
- 1998-08-28 ME MEP-2008-200A patent/ME00122B/me unknown
- 1998-08-28 UA UA2000031729A patent/UA71898C2/uk unknown
- 1998-08-28 EP EP98942180A patent/EP1009388B1/en not_active Expired - Lifetime
- 1998-08-28 AT AT98942180T patent/ATE548029T1/de active
- 1998-08-28 AR ARP980104323A patent/AR017026A1/es not_active Application Discontinuation
- 1998-08-28 CA CA002301685A patent/CA2301685C/en not_active Expired - Fee Related
- 1998-08-28 AU AU90291/98A patent/AU741846B2/en not_active Ceased
- 1998-08-28 WO PCT/US1998/017342 patent/WO1999011244A1/en active Application Filing
- 1998-08-28 CZ CZ20000604A patent/CZ302339B6/cs not_active IP Right Cessation
- 1998-08-28 CN CNB988103753A patent/CN100453074C/zh not_active Expired - Fee Related
- 1998-08-28 HU HU0002797A patent/HUP0002797A3/hu unknown
- 1998-08-28 IL IL13456898A patent/IL134568A/xx not_active IP Right Cessation
- 1998-08-28 RS YU11100A patent/RS52096B/sr unknown
- 1998-08-28 SG SG200203462A patent/SG121718A1/en unknown
- 1998-08-28 EA EA200000267A patent/EA002162B1/ru not_active IP Right Cessation
-
2000
- 2000-02-14 NO NO20000735A patent/NO327752B1/no not_active IP Right Cessation
-
2001
- 2001-08-13 HK HK01105631.3A patent/HK1035135A1/xx not_active IP Right Cessation
-
2002
- 2002-03-11 NZ NZ517736A patent/NZ517736A/en not_active IP Right Cessation
-
2010
- 2010-03-01 JP JP2010044187A patent/JP2010168388A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00122B (me) | Sistemi koji obezbjeđuju podržano oslobađanje lijeka | |
| JP2003517425A5 (me) | ||
| EP0521074B1 (en) | Dosage form for delivering drug to the intestine | |
| US3699963A (en) | Therapeutic adhesive patch | |
| US5455043A (en) | Device for controlled release of vaporous medications through nasal route | |
| US3598123A (en) | Bandage for administering drugs | |
| KR920703026A (ko) | 부하제를 포함한 장기간 전달 장치 | |
| US4721613A (en) | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use | |
| US4863744A (en) | Intestine drug delivery | |
| US5260068A (en) | Multiparticulate pulsatile drug delivery system | |
| US5230898A (en) | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof | |
| AU1824299A (en) | Polymeric microporous film coated subcutaneous implants | |
| CN115475048B (zh) | 滥用和误用制止透皮系统 | |
| US6139868A (en) | Transdermal therapeutic system, its use and production process | |
| DE69227187D1 (de) | Arzneistoffabgabesysteme mit verzögerter freisetzung | |
| ATE238774T1 (de) | Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt | |
| DE69619668D1 (de) | Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon | |
| BRPI0617097A2 (pt) | dispositivo médico, processo de fabricação de dispositivo médico, método de ativação da eluição de óxido nìtrico (no) e método de tratamento | |
| GR3022337T3 (en) | Therapeutical composition and process for its preparation. | |
| ATE285228T1 (de) | Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt | |
| CN100571689C (zh) | 具有改良的长期附着舒适性的透皮治疗体系 | |
| US4851231A (en) | System for delivering drug in selected environment of use | |
| JPH05500511A (ja) | 送達開始を遅延させた経皮送達装置 | |
| US4948593A (en) | Osmotic dosage form comprising an estrogen and a progestogen | |
| US5167962A (en) | Filament system for delivering a medicament and method |